Which anticholinergic drug for overactive bladder symptoms in adults-Reference-Cited by-同舟云学术

Which anticholinergic drug for overactive bladder symptoms in adults

Published:2012-01-18 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Madhuvrata Priya¹,Cody June D²,Ellis Gaye³,Herbison G Peter⁴,Hay-Smith E. Jean C⁵

Affiliation:

1. Sheffield Teaching Hospital NHS Foundation Trust; Obstetrics & Gynaecology; Jessop Wing, Level 4, Room 117 Tree Root Walk Sheffield UK S10 2SF

2. University of Aberdeen; Cochrane Incontinence Review Group; 2nd Floor, Health Sciences Building Health Sciences Building Foresterhill Aberdeen UK AB25 2ZD

3. University of Otago; Women's and Children's Health; PO Box 913 Dunedin New Zealand 9001

4. Dunedin School of Medicine, University of Otago; Department of Preventive & Social Medicine; PO Box 913 Dunedin New Zealand 9054

5. University of Otago; Rehabilitation Teaching and Research Unit, Department of Medicine; Wellington New Zealand

Publisher

Wiley

Subject

Pharmacology (medical)

Reference241 articles.

1. Abrams P Jackson S Mattiasson A Krishnan K Haendler L A randomised, double-blind, placebo controlled, dose ranging study of the safety and efficacy of tolterodine in patients with hyperreflexia Proceedings of the International Continence Society, 26th Annual Meeting, 27-30 Aug; Athens, Greece 1996 276 7

2. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder;Abrams;British Journal of Urology,1998

3. Efficacy and tolerability of tolterodine vs. oxybutynin and placebo in patients with detrusor instability (Abstract);Abrams;Journal of Urology,1997

4. Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome;Abrams;International Journal of Urology,2006

5. Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial;Altan-Yaycioglu;British Journal of Clinical Pharmacology,2005

Cited by 162 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mirabegron 50 mg once daily, long-term treatment maximizes benefit in middle-aged and older people with overactive bladder syndrome: a systematic review and meta-analysis of nine phase II/III, randomized, double-blind, parallel-design, placebo-controlled, multicenter, and multinational trials;Frontiers in Surgery;2024-08-26

2. Management of overactive bladder: consensus statements from the Hong Kong Urological Association and the Hong Kong Geriatrics Society;Hong Kong Medical Journal;2024-08-14

3. Predictors for symptom improvement in overactive bladder patients treated with imidafenacin;Journal of Inclusion Phenomena and Macrocyclic Chemistry;2024-04-05

4. Radiofrequency as the New Opportunity in Treating Overactive Bladder and Urge Urinary Incontinence—A Single-Arm Pilot Study;Medicina;2024-01-24

5. The Use of Metformin in Overactive Bladder: A Retrospective Nested Case-control, Population-based Analysis;Urology;2024-01